Management of the older person after MI

Comprehensive Therapy

Volumn 23, Issue 4, 1997, Pages 259-268

  Aronow, Wilbert S ^a  

^a HEBREW HOSPITAL HOME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOFIBRATE; NICOTINIC ACID; SIMVASTATIN;

CIGARETTE SMOKING; CORONARY RISK; DIABETES MELLITUS; DIET THERAPY; DYSLIPIDEMIA; EXERCISE; HEART INFARCTION; HUMAN; HYPERTENSION; OBESITY; PATIENT CARE; REVIEW; RISK MANAGEMENT; SMOKING CESSATION;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGING; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; CALCIUM CHANNEL BLOCKERS; CARDIOPULMONARY BYPASS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PROGNOSIS; RISK FACTORS;

EID: 0030986326     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Siegel D, Kuller L, Lazarus NB, et al. Predictors of cardiovascular events and mortality in the Systolic Hypertension in the Elderly Program pilot project. Am J Epidemiol. 1987;126:385-399.
2. LaCroix AZ, Lang I, Scherr P, et al. Smoking and mortality among older men and women in three communities. N Engl J Med. 1991;324:1619-1625.
3. Hermanson B, Omenn GS, Kronmal RA, Gersh BJ. Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease: results from the CASS registry. N Engl J Med. 1988;319:1365-1369.
4. Aronow WS, Ahn C. Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease. Am J Cardiol. 1996;77:864-866.
5. Applegate WB. Hypertension in elderly patients. Ann Intern Med. 1989;110:901-915.
6. 1993 Joint National Committee. The Fifth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
7. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on Hypertension in Elderly Trial. Lancet. 1985;1:1349-1354.
8. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP Hypertension). Lancet. 1991;338:1281-1285.
9. MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405-412.
10. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
11. Castelli WP, Wilson PWF, Levy D, Anderson K. Cardiovascular disease in the elderly. Am J Cardiol. 1989;63:12H-19H.
12. Wong ND, Wilson PWF, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Ann Intern Med. 1991;115:687-693.
13. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405-418.
14. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
15. Vokonas PS, Kannel WB. Epidemiology of coronary heart disease in the elderly. In: Tresch DD, Aronow WS, eds. Cardiovascular Disease in the Elderly Patient. New York, NY: Marcel Dekker; 1994:91-123.
16. Donahue RP, Abbott RD, Reed DM, Yano K. Physical activity and coronary heart disease in middle-aged and elderly men: the Honolulu Heart Program. Am J Public Health. 1988;78:683-685.
17. Wenger NK. Physical inactivity as a risk factor for coronary heart disease in the elderly. Cardiol Elderly. 1994;2:375-379.
18. Williams MA, Maresh CM, Aronow WS, et al. The value of early out-patient cardiac exercise programmes for the elderly in comparison with other selected age groups. Eur Heart J. 1984;5(suppl E):113-115.
19. Cairns JA, Lewis HD Jr, Meade TW, et al. Antithrombotic agents in coronary artery disease. Chest. 1995;108(suppl):380S-400S.
20. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
21. The Sixty Plus Reinfarction Study Group. A double-blind trial to assess long-term oral anti-coagulant therapy in elderly patients after myocardial infarction. Lancet. 1980;2:989-994.
22. Smith P, Arnesen H, Holme I. Effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med. 1990;323:147-152.
23. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group, Effects of long-term oral anti-coagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet. 1994;343:499-503.
24. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA. 1993;270:1589-1595.
25. Hansteen V. Beta blockade after myocardial infarction: the Norwegian Propranolol Study in high-risk patients. Circulation. 1983;67(suppl I):I-57-I-60.
26. Hjalmarson A, Herbiz J, Malek J, et al. Effect on mortality of metoprolol in acute myocardial infarction. Lancet. 1981;2:823-827.
27. Gundersen T, Abrahamsen AM, Kjekshus J, et al. Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction. Circulation. 1982;66:1179-1184.
28. Pedersen TR (for the Norwegian Multicentre Study Group). Six-year follow-up of the Norwegian Multicentre Study on Timolol after acute myocardial infarction. N Engl J Med. 1985;313:1055-1058.
29. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA. 1982;247:1707-1714.
30. Park KG, Forman DE, Wei JY. Utility of beta-blockade treatment for older postinfarction patients. J Am Geriatr Soc. 1995;43:751-755.
31. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 1986;73:503-510.
32. Aronow WS, Ahn G, Mercando AD, et al. Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients ≥62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction ≥40%. Am J Cardiol. 1994;74:267-270.
33. Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol. 1994;74:674-680.
34. Aronow WS, Ahn C, Mercando AD, et al. Decrease of mortality by propranolol in patients with heart disease and complex ventricular arrhythmias is more an anti-ischemic than an antiarrhythmic effect. Am J Cardiol 1994;74:613-615.
35. Aronow WS, Ahn C, Mercando AD, Epstein S. Effect of propranolol on circadian variation of ventricular arrhythmias in elderly patients with heart disease and complex ventricular arrhythmias. Am J Cardiol. 1995;75:514-516.
36. Aronow WS, Ahn C, Mercando AD, Epstein S. Effect of propranolol on circadian variation of myocardial ischemia in elderly patients with heart disease and complex ventricular arrhythmias. Am J Cardiol. 1995;75:837-839.
37. Aronow WS, Ahn C, Mercando AD, Epstein S. Circadian variation of sudden cardiac death or fatal myocardial infarction is abolished by propranolol in patients with heart disease and complex ventricular arrhythmias. Am J Cardiol. 1994;74:819-821.
38. Yusuf S, Wittes J, Probstfield J. Evaluating effects of treatment subgroups of patients within a clinical trial: the case of non-Q-wave myocardial infarction and beta blockers. Am J Cardiol. 1990;60:220-222.
39. Danahy DT, Aronow WS. Hemodynamics and antianginal effects of high dose oral isorbide dinitrate after chronic use. Circulation. 1977;56:205-212.
40. Parker JO, Farrell B, Lahey KA, et al. Effect of interval between doses on the development of tolerance to isosorbide dinitrate. N Engl J Med. 1987;316:1440-1444.
41. Cohn J, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
42. Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol. 1993;71:602-604.
43. Garg R, Yusuf S (for the Collaborative Group on ACE Inhibitor Trials). Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273:1450-1456.
44. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669-677.
45. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
46. Ambrosioni E, Borghi G, Magnani B (for the Survival of Myocardial Infarction Long-Term Evaluation [SMILE] Study Investigators). The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 1995;332:80-85.
47. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670-1676.
48. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol. 1991;67:1295-1297.
49. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-1321.
50. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319:385-392.
51. Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation. 1991;83:52-60.
52. Danish Study Group on Verapamil in Myocardial Infarction. Trial II-DAVIT II. Effect of verapamil on mortality and major events after acute myocardial infarction. Ann J Cardiol. 1990;66:779-785.
53. Akiyama T, Pawitan Y, Campbell WB, et al. Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. J Am Geriatr Soc. 1992;40:666-672.
54. Aronow WS, Mercando AD, Epstein S, Kronzon I. Effect of quinidine or procainamide versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in elderly patients with heart disease and complex ventricular arrhythmias. Am J Cardiol. 1990;66:423-428.
55. Waldo AL, Camm AJ, de Ruyter PL, et al. Preliminary mortality results from the Survival with Oral D-Sotalol (SWORD) Trial. J Am Coll Cardiol. 1995;25:15A. Abstract.
56. Greene HL (for the CASCADE Investigators). The CASCADE study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. Am J Cardiol. 1993;72:70F-74F.
57. Herre J, Sauve M, Malone P, et al. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol. 1989;13:442-449.
58. Friedman LM, Byington RP, Capone RJ, et al. Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia. J Am Coll Cardiol. 1986;7:1-8.
59. Norris RM, Barnaby PF, Brown MA, et al. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet. 1984;2:883-886.
60. Tresch DD, Troup PJ, Thakur RK, et al. Comparison of efficacy of automatic implantable cardioverter defibribrilator in patients older and younger than 65 years of age. Am J Med. 1991;90:717-724.
61. Grodstein F, Stampfer MJ. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis. 1995;38:199-210.
62. Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med. 1994;154:1333-1339.
63. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453-461.
64. The Postmenopausal Estrogen/Progestin Interventions Trial Writing Group. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995;273:199-208.
65. Rahimtoola SH, Fessler CL, Grunkemeier GL, et al. Survival 15 to 20 years after coronary bypass surgery for angina. J Am Coll Cardiol. 1993;21:151-157.
66. Weintraub WS, Clements SD, Ware J, et al. Coronary artery surgery in octogenarians. Am J Cardiol. 1991;68:1530-1534.
67. Buffet P, Danchin N, Juilliere Y, et al. Percutaneous transluminal coronary angioplasty in patients more than 75 years old: early and long-term results. Int/Cardiol. 1992;37:33-39.
68. Thompson RC, Holmes DR Jr, Gersh BJ, et al. Percutaneous transluminal coronary angioplasty in the elderly: early and long-term results. J Am Coll Cardiol. 1991; 17:1245-1250.